"I'd redirect investors to a company called Galena Biopharma (NASDAQ: GALE ) , which has a newly launched product that treats the same indication."
" However, with proven success in Europe and a market cap of just $200 million, Galena presents a far greater risk/reward ratio versus Insys at $1 billion. If Abstral is successful, Galena could be the second coming of Insys. And as a consequence of success, Abstral might eat away at Subsys' sales, disappointing investors seeking rapid growth. Hence, I'd take profits in shares of Insys."